youtube_live
Q3 2026 earnings • released • EPS beat +15.39% • Revenue beat +5.58%
See resultschevron_right
SBRA:NASDAQ
Sabra Health Care REIT Inc
$19.72
arrow_downward
-0.10%(-0.020) 1D
$19.72
0.00% (0.00)
bedtimeAfter hours
Closed: Nov 2, 4:00:01 PM GMT-5 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for SBRA...
Open
$19.93
High
$19.93
Low
$19.63
Mkt. cap
5.04B
Avg. vol.
2.33M
Volume
3.40M
Dividend
6.09%
Quarterly dividend
$0.30
Ex-dividend date
Aug 14, 2026
P/E ratio
75.88
52-wk high
$22.77
52-wk low
$17.54
EPS
$0.26
Beta
0.65
Shares outstanding
255.46M
No. of employees
58
Open
$19.93
High
$19.93
Low
$19.63
Mkt. cap
5.04B
Avg. vol.
2.33M
Volume
3.40M
Dividend
6.09%
Quarterly dividend
$0.30
Ex-dividend date
Aug 14, 2026
P/E ratio
75.88
52-wk high
$22.77
52-wk low
$17.54
EPS
$0.26
Beta
0.65
Shares outstanding
255.46M
No. of employees
58
News stories
From web sources and news partners
TradingView
·
1 hour ago
Sabra Health Care REIT, Inc. reports results for the quarter ended September 30 - Earnings Summary
Zacks
·
3 hours ago
Sabra Healthcare (SBRA) Tops Q3 FFO and Revenue Estimates
GuruFocus
·
3 hours ago
Sabra Health Care REIT Inc Reports Q3 2026 Earnings: Revenue Sur
Yahoo Finance
·
4 hours ago
Sabra Healthcare (SBRA) Tops Q3 FFO and Revenue Estimates
About Sabra Health Care REIT Inc
CEO-
Employees58
Founded2010
HeadquartersTustin, California, United States
SectorReal estate investment trust
Websitesabrahealth.com
Analyst ratings
Based on 9 analysts giving stock ratings to SBRA in the past 3 months
Buy
Buy
4
Hold
5
Sell
0
12-month forecast
Based on 9 Wall Street analysts offering 12 month price targets for SBRA in the last 3 months.
Highest
Current $19.72
$24.00 (+21.70%)
Average
$21.88 (+10.95%)
Lowest
$20.00 (+1.42%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
John Kilichowski Wells Fargo | Buy | Reiterated | $21.00 | +6.5% | 10/19/2026 |
Michael Goldsmith UBS | Hold | Reiterated | $20.00 | +1.4% | 10/13/2026 |
Richard Hightower Barclays | Hold | Maintained | $21.00 | +6.5% | 10/13/2026 |
Robert Stevenson Janney Montgomery | Buy | Initiated | $23.00 | +16.6% | 09/09/2026 |
Unknown Analyst Wells Fargo | Buy | Maintained | $23.00 | +16.6% | 09/01/2026 |
Vikram Malhotra Mizuho Securities | Hold | Maintained | $21.00 | +6.5% | 08/31/2026 |
Farrell Granath Bank of America Securities | Buy | Maintained | - | - | 08/17/2026 |
Michael Lewis Truist Financial | Buy | Maintained | $24.00 | +21.7% | 08/13/2026 |
Richard Anderson Cantor Fitzgerald | Hold | Maintained | $22.00 | +11.6% | 08/10/2026 |
Dave Rodgers Raymond James | Hold | Upgraded | $23.00 | +16.6% | 08/06/2026 |
Omotayo Okusanya Deutsche Bank | Buy | Maintained | $25.00 | +26.8% | 07/22/2026 |
Wes Golladay Robert W. Baird | Hold | Maintained | $23.00 | +16.6% | 07/22/2026 |
Aaron Hecht Citizens JMP | Buy | Maintained | $25.00 | +26.8% | 07/22/2026 |
Nicholas Joseph Citi | Hold | Downgraded | $19.00 | -3.7% | 06/23/2026 |
Seth Bergey Citi | Hold | Downgraded | $19.00 | -3.7% | 06/23/2026 |
Nicholas Yulico Scotiabank | Hold | Maintained | $19.00 | -3.7% | 06/18/2026 |
Unknown Analyst Raymond James | Sell | Initiated | $18.73 | -5% | 06/16/2026 |
Juan C. Sanabria BMO Capital | Hold | Maintained | $23.00 | +16.6% | 04/29/2026 |
Last report
Nov 3, 2026
Fiscal period
Q3 2026
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
$0.19 / $0.17
+15.39%beat
arrow_upward
Revenue / Est. (USD)
249.56M / 236.37M
+5.58%beat
arrow_upward
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | 191.26M | 210.75M | 223.66M | 238.09M |
Cost of goods sold | 69.41M | 80.01M | 85.43M | 194.72M |
Cost of revenue | 69.41M | 80.01M | 85.43M | 194.72M |
Research and development expenses | - | - | - | - |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 12.56M | 15.91M | 14.86M | 16.82M |
Operating expense | 62.44M | 63.59M | 67.99M | 73.20M |
Total operating expenses | 131.85M | 143.60M | 153.42M | 267.92M |
Operating income | 59.41M | 67.15M | 70.24M | -29.82M |
Other non operating income | - | -3.66M | -55.00K | 17.00K |
EBT including unusual items | 22.95M | 27.64M | 41.34M | -24.57M |
EBT excluding unusual items | 30.51M | 34.55M | 41.78M | -59.59M |
Income tax expense | 436.00K | 491.00K | 526.00K | 678.00K |
Effective tax rate | 1.90% | 1.78% | 1.27% | -2.76% |
Other operating expenses | 1.37M | -3.72M | - | - |
Net income | 22.54M | 27.22M | 40.88M | -25.20M |
Net profit margin | 11.78% | 12.92% | 18.28% | -10.59% |
Earnings per share | 0.17 | 0.16 | 0.16 | 0.15 |
Interest and investment income | - | - | - | - |
Interest expense | -28.90M | -28.94M | -28.41M | -29.78M |
Net interest expenses | -28.90M | -28.94M | -28.41M | -29.78M |
Depreciation and amortization charges | 48.51M | 51.40M | 53.13M | 56.38M |
EBITDA | 107.92M | 113.68M | 123.37M | 26.55M |
Gain or loss from assets sale | 4.43M | 9.06M | - | -37.72M |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1
Upcoming events